Le moteur de recherche
des thèses françaises
'%3e%3cpath%20d='m45.605%20121.876-4.838%202.639%204.838%202.639%203.958-2.16v3.04h.88v-3.519m-7.917%201.838v1.76l3.079%201.68%203.078-1.68v-1.76l-3.078%201.68z'%20style='fill:%23fff;fill-opacity:1;stroke-width:.439787'/%3e%3cpath%20style='fill:%2300a0dc;fill-opacity:1;stroke:none;stroke-width:.143361;stroke-opacity:1;stop-color:%23000'%20d='M40.31%20119.943h10.388c.457%200%20.824.418.824.937v10.163c0%20.519-.367.937-.824.937H40.31c-.457%200-.824-.418-.824-.938V120.88c0-.52.367-.937.824-.937z'/%3e%3cpath%20d='m45.537%20121.859-4.829%202.633%204.829%202.634%203.95-2.155v3.033h.878v-3.512m-7.9%201.835v1.756l3.072%201.676%203.072-1.676v-1.756l-3.072%201.677z'%20style='fill:%23fff;fill-opacity:1;stroke-width:.438915'/%3e%3ccircle%20style='fill:%23ff8d24;fill-opacity:1;stroke:%23fff;stroke-width:.376436;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1;stop-color:%23000'%20cx='52.554'%20cy='121.07'%20r='3.421'/%3e%3cpath%20d='M52.802%20118.592v.501a1.98%201.98%200%200%201%201.724%202.21%201.98%201.98%200%200%201-1.724%201.724v.495a2.471%202.471%200%200%200%202.217-2.707%202.471%202.471%200%200%200-2.217-2.222m-.496.007a2.435%202.435%200%200%200-1.32.545l.354.366a1.98%201.98%200%200%201%20.966-.416v-.495m-1.67.894a2.448%202.448%200%200%200-.547%201.32h.496c.047-.351.185-.686.406-.966l-.354-.354m-.545%201.816c.05.485.24.944.547%201.32l.352-.354a1.982%201.982%200%200%201-.404-.966h-.495m1.248%201.33-.354.34c.374.311.835.507%201.32.56v-.496a1.981%201.981%200%200%201-.966-.404m1.338-2.816v1.3l1.114.661-.185.305-1.3-.78v-1.486z'%20style='fill:%23fff;fill-opacity:1;stroke-width:.247705'/%3e%3c/g%3e%3c/svg%3e)
Effet de l'inhibition de l'IL-1B par le Gevokizumab sur les dysfonctions cardiaque et vasculaire dans un modèle d'ischémie-reperfusion chez le rat Wistar et le rat GK diabétique
FR
%20Copyright%202023%20Fonticons,%20Inc.%20--%3e%3cstyle%3esvg{fill:%23cf491b;}%3c/style%3e%3cpath%20d='M256%2032c14.2%200%2027.3%207.5%2034.5%2019.8l216%20368c7.3%2012.4%207.3%2027.7%20.2%2040.1S486.3%20480%20472%20480H40c-14.3%200-27.6-7.7-34.7-20.1s-7-27.8%20.2-40.1l216-368C228.7%2039.5%20241.8%2032%20256%2032zm0%20128c-13.3%200-24%2010.7-24%2024V296c0%2013.3%2010.7%2024%2024%2024s24-10.7%2024-24V184c0-13.3-10.7-24-24-24zm32%20224a32%2032%200%201%200%20-64%200%2032%2032%200%201%200%2064%200z'/%3e%3c/svg%3e){kind=icon}
La soutenance a eu lieu le 08/01/2016. Le document qui a justifié du diplôme est en cours de traitement par l'établissement de soutenance.| Auteur / Autrice : | Najah Harouki |
| Direction : | Paul Mulder |
| Type : | Projet de thèse |
| Discipline(s) : | Pharmacologie cardiovasculaire |
| Date : | Inscription en doctorat le 14/09/2012 Soutenance le 08/01/2016 |
| Etablissement(s) : | Rouen |
| Ecole(s) doctorale(s) : | Ecole Doctorale Normande de Biologie Intégrative, Santé, Environnement |
| Partenaire(s) de recherche : | Equipe de recherche : NOUVELLES CIBLES PHARMACOLOGIQUES DE LA PROTECTION ENDOTHELIALE ET DE L'INSUFFISANCE CARDIAQUE |
| Jury : | Président / Présidente : Bijan Ghaleh-marzban |
Mots clés
FR